ClinicalTrials.Veeva

Menu

Interaction Study of Clopidogrel 600/150 mg Given Alone or Concomitantly With Omeprazole 80 mg in Healthy Subjects

Sanofi logo

Sanofi

Status and phase

Completed
Phase 1

Conditions

Healthy

Treatments

Drug: Placebo
Drug: Omeprazole
Drug: Clopidogrel

Study type

Interventional

Funder types

Industry

Identifiers

NCT01129414
INT11208
2009-011005-16 (EudraCT Number)

Details and patient eligibility

About

Primary objective:

  • Assess the effects of clopidogrel (600 mg loading dose followed by 4 days 150 mg/day) on Adenosine diphosphate (ADP)-induced platelet aggregation when given concomitantly with omeprazole 80 mg/day compared to given alone in healthy male and female subjects

Secondary Objective:

  • Compare the pharmacokinetic profiles of clopidogrel and its active metabolite when clopidogrel is given either alone or concomitantly with omeprazole

Full description

The total study duration per subjects is 8 - 9 weeks broken down as follows:

  • Screening: 2 to 21 days before the first dosing (clopidogrel or omeprazole)
  • Period clopidogrel/placebo: 7 days including 5 days treatment
  • Period clopidogrel/placebo + omeprazole: 12 days including 10 days treatment
  • Washout between periods: at least 14 days after last dosing with respect to clopidogrel treatment
  • End of study: 7 to 10 days after the last dosing

Enrollment

72 patients

Sex

All

Ages

18 to 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Healthy subject:

  • as determined by medical history, physical examination including vital signs and clinical laboratory tests:
  • with a body weight between 50 kg and 95 kg if male, between 40 kg and 85 kg if female, and with a Body Mass Index (BMI) between 18 and 30 kg/m²

Exclusion criteria

  • Evidence of inherited disorder of coagulation/hemostasis functions
  • Smoking more than 5 cigarettes or equivalent per day
  • Abnormal hemostasis screen
  • Unability to abstain from intake of any drug affecting hemostasis throughout the whole study duration >Any contraindication to clopidogrel and/or omeprazole

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Trial design

Primary purpose

Basic Science

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Double Blind

72 participants in 4 patient groups, including a placebo group

Group clopidogrel - clopidogrel + omeprazole
Experimental group
Description:
Period 1: * Day 1: clopidogrel 600 mg loading dose * Day 2 to Day 5: clopidogrel 150 mg, once daily Period 2: * Day -5 to Day -1: omeprazole 80 mg, once daily * Day 1: clopidogrel 600 mg loading dose + omeprazole 80 mg concomitantly * Day 2 to Day 5: clopidogrel 150 mg + omeprazole 80 mg concomitantly, once daily Each intake is under fasted conditions
Treatment:
Drug: Clopidogrel
Drug: Omeprazole
Group placebo - placebo + omeprazole
Placebo Comparator group
Description:
Period 1: * Day 1: placebo loading dose * Day 2 to Day 5: placebo, once daily Period 2: * Day -5 to Day -1: omeprazole 80 mg, once daily * Day 1: placebo loading dose + omeprazole 80 mg concomitantly * Day 2 to Day 5: placebo + omeprazole 80 mg concomitantly, once daily Each intake is under fasted conditions
Treatment:
Drug: Omeprazole
Drug: Placebo
Group clopidogrel + omeprazole - clopidogrel
Experimental group
Description:
Period 1: * Day -5 to Day -1: omeprazole 80 mg, once daily * Day 1: clopidogrel 600 mg loading dose + omeprazole 80 mg concomitantly * Day 2 to Day 5: clopidogrel 150 mg + omeprazole 80 mg concomitantly, once daily Period 2: * Day 1: clopidogrel 600 mg loading dose * Day 2 to Day 5: clopidogrel 150 mg, once daily Each intake is under fasted conditions
Treatment:
Drug: Clopidogrel
Drug: Omeprazole
Group placebo + omeprazole placebo
Placebo Comparator group
Description:
Period 1: * Day -5 to Day -1: omeprazole 80 mg, once daily * Day 1: placebo loading dose + omeprazole 80 mg concomitantly * Day 2 to Day 5: placebo + omeprazole 80 mg concomitantly, once daily Period 2: * Day 1: placebo loading dose * Day 2 to Day 5: placebo, once daily Each intake is under fasted conditions
Treatment:
Drug: Omeprazole
Drug: Placebo

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems